C
Clemensia Nakabiito
Researcher at Johns Hopkins University
Publications - 49
Citations - 5611
Clemensia Nakabiito is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Population & Nevirapine. The author has an hindex of 20, co-authored 42 publications receiving 5199 citations. Previous affiliations of Clemensia Nakabiito include Makerere University & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
Laura Guay,Philippa Musoke,Thomas Fleming,Danstan Bagenda,Melissa Allen,Clemensia Nakabiito,Joseph Sherman,Paul M Bakaki,Constance Ducar,Martina Deseyve,Lynda Emel,Mark Mirochnick,Mary Glenn Fowler,Lynne M. Mofenson,Paolo G. Miotti,Kevin Dransfield,Dorothy Bray,Francis Mmiro,J. Brooks Jackson +18 more
TL;DR: Nevirapine lowered the risk of HIV-1 transmission during the first 14-16 weeks of life by nearly 50% in a breastfeeding population, suggesting this simple and inexpensive regimen could decrease mother-to-child HIV- 1 transmission in less-developed countries.
Journal ArticleDOI
Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women
Jeanne M. Marrazzo,Gita Ramjee,Barbra A. Richardson,Kailazarid Gomez,Nyaradzo Mgodi,Gonasagrie Nair,Thesla Palanee,Clemensia Nakabiito,Ariane van der Straten,Lisa M. Noguchi,Craig W. Hendrix,James Y. Dai,S. Ganesh,Baningi Mkhize,Marthinette Taljaard,Urvi M. Parikh,Jeanna M. Piper,Benoît Mâsse,Benoît Mâsse,Cynthia I. Grossman,James F. Rooney,Jill L. Schwartz,Heather Watts,Mark A. Marzinke,Sharon L. Hillier,Ian McGowan,Z. Mike Chirenje +26 more
TL;DR: None of the drug regimens evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis, and adherence to study drugs was low.
Journal ArticleDOI
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial
J. Brooks Jackson,Philippa Musoke,Thomas Fleming,Thomas Fleming,Laura Guay,Danstan Bagenda,Melissa Allen,Clemensia Nakabiito,Joseph Sherman,Paul M Bakaki,Maxensia Owor,Constance Ducar,Martina Deseyve,Anthony Mwatha,Lynda Emel,Corey Duefield,Mark Mirochnick,Mary Glenn Fowler,Lynne M. Mofenson,Paolo G. Miotti,Maria Gigliotti,Dorothy Bray,Francis Mmiro +22 more
TL;DR: Intrapartum/ne ononatal nevirapine significantly lowered HIV-1 transmission risk in a breastfeeding population in Uganda compared with a short intrapartu/neonatal zidovudine regimen.
Journal ArticleDOI
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
Jared M. Baeten,Thesla Palanee-Phillips,Elizabeth R. Brown,Elizabeth R. Brown,Katie Schwartz,Lydia Soto-Torres,Vaneshree Govender,Nyaradzo Mgodi,Flavia Matovu Kiweewa,Gonasagrie Nair,Felix Mhlanga,Samantha Siva,Linda-Gail Bekker,Nitesha Jeenarain,Zakir Gaffoor,Francis Martinson,Bonus Makanani,Arendevi Pather,Logashvari Naidoo,Marla Husnik,Marla Husnik,Barbra A. Richardson,Barbra A. Richardson,Urvi M. Parikh,John W. Mellors,Mark A. Marzinke,Craig W. Hendrix,Ariane van der Straten,Ariane van der Straten,Gita Ramjee,Zvavahera M. Chirenje,Clemensia Nakabiito,Taha E. Taha,Judith G. Jones,Ashley J Mayo,Rachel Scheckter,Jennifer Berthiaume,Edward Livant,Cindy Jacobson,Patrick Ndase,Rhonda White,Karen Patterson,Donna Germuga,Beth Galaska,Katherine E. Bunge,Devika Singh,Daniel W. Szydlo,Elizabeth T. Montgomery,Barbara S. Mensch,Kristine Torjesen,Cynthia I. Grossman,Nahida Chakhtoura,Annalene Nel,Zeda F. Rosenberg,Ian McGowan,Sharon L. Hillier +55 more
TL;DR: A monthly vaginal ring containing dapivirine reduced the risk of HIV-1 infection among African women, with increased efficacy in subgroups with evidence of increased adherence.
Journal ArticleDOI
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Six Week Extended-Dose Nevirapine (Swen) Study Team,Abubaker Bedri,Berhanu Gudetta,Abdulhamid Isehak,Solomon Kumbi,Sileshi Lulseged,Yohannes Mengistu,Arvind V. Bhore,Ramesh Bhosale,Venkat Varadhrajan,Nikhil Gupte,Jayagowri Sastry,Nishi Suryavanshi,Srikanth Tripathy,Francis Mmiro,Michael Mubiru,Carolyne Onyango,Adrian Taylor,Philippa Musoke,Clemensia Nakabiito,Aida Abashawl,Rahel Adamu,Gretchen Antelman,Robert C. Bollinger,Patricia Bright,Mohammad A Chaudhary,Jacqueline S. Coberly,Laura Guay,Mary Glenn Fowler,Amita Gupta,Elham Hassen,J. Brooks Jackson,Lawrence H. Moulton,Uma Nayak,Saad B. Omer,Lidia Propper,Malathi Ram,Vivian Rexroad,Andrea Ruff,Anita V. Shankar,Sheryl Zwerski +40 more
TL;DR: It is suggested that a longer course of daily infant nevirapine to prevent HIV transmission via breast milk might be more effective where access to affordable and safe replacement feeding is not yet available and where the risks of replacement feeding are high.